Home › Companies › ADMA

Adma Biologics

ADMA Lead: Approved 1 Biotech Distilled article ↓

Infectious Disease Protein

Most recent annual filing: 2026-02-25

Pipeline (4 active programs)

ASCENIV

Immune Globulin Intravenous, Human – slra 10% Liquid · RI-002

Protein Target: RSV neutralizing antibodies

Primary Humoral Immunodeficiency Approved intravenous

Nabi-HB

Hepatitis B Immune Globulin, Human

Protein Target: Hepatitis B antibodies

Hepatitis B Approved intramuscular

S. pneumoniae hyperimmune globulin

SG-001

Protein Target: S. pneumoniae antibodies

Pneumococcal Pneumonia Preclinical

BIVIGAM

Immune Globulin Intravenous, Human

Protein Target: polyclonal antibodies

Primary Humoral Immunodeficiency Approved intravenous

Biotech Distilled coverage (1)

2026-07-06 ADMA Biologics (ADMA) — Scientific Deep Dive for ASCENIV, BIVIGAM, Nabi-HB, and the SG-001 Pipeline

Articles open on Substack. Some deep dives are subscriber-only.